Predictive Model for Early Detection of Mild Cognitive Impairment and Alzheimer’s Disease

Author(s):  
Eva K. Lee ◽  
Tsung-Lin Wu ◽  
Felicia Goldstein ◽  
Allan Levey
2017 ◽  
Vol 33 (6) ◽  
pp. 832-840 ◽  
Author(s):  
Elina Boycheva ◽  
Israel Contador ◽  
Bernardino Fernández-Calvo ◽  
Francisco Ramos-Campos ◽  
Verónica Puertas-Martín ◽  
...  

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Sergio Grueso ◽  
Raquel Viejo-Sobera

Abstract Background An increase in lifespan in our society is a double-edged sword that entails a growing number of patients with neurocognitive disorders, Alzheimer’s disease being the most prevalent. Advances in medical imaging and computational power enable new methods for the early detection of neurocognitive disorders with the goal of preventing or reducing cognitive decline. Computer-aided image analysis and early detection of changes in cognition is a promising approach for patients with mild cognitive impairment, sometimes a prodromal stage of Alzheimer’s disease dementia. Methods We conducted a systematic review following PRISMA guidelines of studies where machine learning was applied to neuroimaging data in order to predict whether patients with mild cognitive impairment might develop Alzheimer’s disease dementia or remain stable. After removing duplicates, we screened 452 studies and selected 116 for qualitative analysis. Results Most studies used magnetic resonance image (MRI) and positron emission tomography (PET) data but also magnetoencephalography. The datasets were mainly extracted from the Alzheimer’s disease neuroimaging initiative (ADNI) database with some exceptions. Regarding the algorithms used, the most common was support vector machine with a mean accuracy of 75.4%, but convolutional neural networks achieved a higher mean accuracy of 78.5%. Studies combining MRI and PET achieved overall better classification accuracy than studies that only used one neuroimaging technique. In general, the more complex models such as those based on deep learning, combined with multimodal and multidimensional data (neuroimaging, clinical, cognitive, genetic, and behavioral) achieved the best performance. Conclusions Although the performance of the different methods still has room for improvement, the results are promising and this methodology has a great potential as a support tool for clinicians and healthcare professionals.


2021 ◽  
Author(s):  
Sergio Grueso ◽  
Raquel Viejo-Sobera

Abstract Background: Increase in life-span in our society is a double-edged sword that entails a growing number of patients with neurocognitive disorders, Alzheimer’s disease being the most prevalent. Advances in medical imaging and computational power, enable new methods for early detection of neurocognitive disorders with the goal of preventing or reducing cognitive decline. Computer-aided image analysis and early detection of changes in cognition is a promising approach for patients with mild cognitive impairment, sometimes a prodromal stage of Alzheimer’s disease.Methods: We conducted a systematic review following PRISMA guidelines of studies where Machine Learning was applied to neuroimaging data in order to predict the progression from Mild Cognitive Impairment to Alzheimer’s disease. After removing duplicates, we screened 159 studies and selected 47 for a qualitative analysis. Results: Most studies used Magnetic Resonance Image and Positron Emission Tomography data but also Magnetoencephalography. The datasets were mainly extracted from the Alzheimer’s disease Neuroimage Initiative (ADNI) database with some exceptions. Regarding the algorithms used, the most common were support vector machines, but more complex models such as Deep Learning, combined with multimodal and multidimensional data (neuroimaging, clinical, cognitive, biological, and behavioral) achieved the best performance. Conclusions: Although performance of the different models still has room for improvement, the results are promising and this methodology has a great potential as a support tool for clinicians and healthcare professionals.


2021 ◽  
Author(s):  
Sergio Grueso ◽  
Raquel Viejo-Sobera

Increase in life-span in our society is a double-edged sword that entails a growing number of patients with neurocognitive disorders, Alzheimer’s disease (AD) being the most prevalent. Advances in medical imaging and computational power, enable new methods for early detection of neurocognitive disorders with the goal of preventing or reducing cognitive decline. Computer-aided image analysis and early detection of changes in cognition is a promising approach for patients with mild cognitive impairment (MCI), sometimes a prodromal stage of AD. We conducted a systematic review following PRISMA guidelines of studies where Machine Learning was applied to neuroimaging data in order to predict the progression from MCI to AD. After removing duplicates, we screened 159 studies and selected 47 for a qualitative analysis. Most studies used MRI and PET data but also MEG. The datasets were mainly extracted from the ADNI database with some exceptions. Regarding the algorithms used, the most common were support vector machines, but more complex models such as Deep Learning, combined with multimodal and multidimensional data (neuroimage, clinical, cognitive, biological, and behavioral) achieved the best performance. Although performance of the different models still have room for improvement, the results are promising and this methodology has a great potential as a support tool for clinicians and healthcare professionals.


2021 ◽  
Author(s):  
Dong-Woo Ryu ◽  
Yun Jeong Hong ◽  
Jung Hee Cho ◽  
Kichang Kwak ◽  
Jong-Min Lee ◽  
...  

Abstract A quantitative analysis of brain volume can assist in diagnosis of Alzheimer’s disease (AD) ususally accompannied by brain atrophy. With an automated analysis program Quick Brain Volumetry (QBraVo) developed for volumetric measurements, we measured regional volumes and ratios to evaluate their performance in discriminating AD dementia (ADD) and mild cognitive impairment (MCI) patients from normal controls (NC). Validation of QBraVo was based on intra-rater and inter-rater reliability with a manual measurement. The regional volumes and ratios to total intracranial volume (TIV) and to total brain volume (TBV) or total cerebrospinal fluid volume (TCV) were compared among subjects. The regional volume to total cerebellar volume ratio named Standardized Atrophy Volume Ratio (SAVR) was calculated to compare brain atrophy. Diagnostic performances to distinguish among NC, MCI, and ADD were compared between MMSE, SAVR, and the predictive model. In total, 56 NCs, 44 MCI, and 45 ADD patients were enrolled. The average run time of QBraVo was 5 minutes 36 seconds. Intra-rater reliability was 0.999. Inter-rater reliability were high for TBV, TCV, and TIV (R = 0.97, 0.89 and 0.93, respectively). The medial temporal SAVR showed the highest performance for discriminating ADD from NC (AUC = 0.808, diagnostic accuracy = 80.2%). The predictive model using both MMSE and medial temporal SAVR improved the diagnostic performance for MCI in NC (AUC = 0.844, diagnostic accuracy = 79%). Our results demonstrated QBraVo as a fast and accurate method to measure brain volume. The regional volume calculated as SAVR could help to diagnose ADD and MCI and increase diagnostic accuracy for MCI.


Sign in / Sign up

Export Citation Format

Share Document